Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Euro Surveill ; 26(21)2021 05.
Article in English | MEDLINE | ID: mdl-34047273

ABSTRACT

The hospital water environment, including the wastewater drainage system, is increasingly reported as a potential reservoir for carbapenemase-producing Enterobacterales (CPE). We investigated a persistent outbreak of OXA-48 CPE (primarily Citrobacter freundii) in a haematological ward of a French teaching hospital by epidemiological, microbiological and environmental methods. Between January 2016 and June 2019, we detected 37 new OXA-48 CPE-colonised and/or ­infected patients in the haematological ward. In October 2017, a unit dedicated to CPE-colonised and/or ­infected patients was created. Eleven additional sporadic acquisitions were identified after this date without any obvious epidemiological link between patients, except in one case. Environmental investigations of the haematological ward (June-August 2018) identified seven of 74 toilets and one of 39 drains positive for OXA-48 CPE (seven C. freundii, one Enterobacter sakazakii, one Escherichia coli). Whole genome comparisons identified a clonal dissemination of OXA-48-producing C. freundii from the hospital environment to patients. In addition to strict routine infection control measures, an intensive cleaning programme was performed (descaling and bleaching) and all toilet bowls and tanks were changed. These additional measures helped to contain the outbreak. This study highlights that toilets can be a possible source of transmission of OXA-48 CPE.


Subject(s)
Cross Infection/microbiology , Disease Outbreaks , Enterobacteriaceae Infections/microbiology , Toilet Facilities , Bacterial Proteins , Citrobacter freundii/enzymology , Cronobacter sakazakii/enzymology , Disease Reservoirs/microbiology , Escherichia coli/enzymology , France/epidemiology , Hospitals , Humans , Infection Control , Water Microbiology , beta-Lactamases/genetics
2.
Emerg Infect Dis ; 26(7): 1526-1528, 2020 07.
Article in English | MEDLINE | ID: mdl-32568063

ABSTRACT

We describe 2 cases of healthcare-associated Legionnaires' disease in patients in France hospitalized 5 months apart in the same room. Whole-genome sequencing analyses showed that clinical isolates from the patients and isolates from the room's toilet clustered together. Toilet contamination by Legionella pneumophila could lead to a risk for exposure through flushing.


Subject(s)
Bathroom Equipment , Cross Infection , Legionella pneumophila , Legionnaires' Disease , France , Humans , Legionella pneumophila/genetics , Legionnaires' Disease/diagnosis , Legionnaires' Disease/epidemiology
3.
Int J Pharm ; 515(1-2): 114-124, 2016 Dec 30.
Article in English | MEDLINE | ID: mdl-27720874

ABSTRACT

The purpose of this work was to increase the solubility and the dissolution rate of itraconazole, which was chosen as the model drug, by obtaining an amorphous solid dispersion by hot melt extrusion. Therefore, an initial preformulation study was conducted using differential scanning calorimetry, thermogravimetric analysis and Hansen's solubility parameters in order to find polymers which would have the ability to form amorphous solid dispersions with itraconazole. Afterwards, the four polymers namely Kollidon® VA64, Kollidon® 12PF, Affinisol® HPMC and Soluplus®, that met the set criteria were used in hot melt extrusion along with 25wt.% of itraconazole. Differential scanning confirmed that all four polymers were able to amorphize itraconazole. A stability study was then conducted in order to see which polymer would keep itraconazole amorphous as long as possible. Soluplus® was chosen and, the formulation was fine-tuned by adding some excipients (AcDiSol®, sodium bicarbonate and poloxamer) during the hot melt extrusion process in order to increase the release rate of itraconazole. In parallel, the range limits of the hot melt extrusion process parameters were determined. A design of experiment was performed within the previously defined ranges in order to optimize simultaneously the formulation and the process parameters. The optimal formulation was the one containing 2.5wt.% of AcDiSol® produced at 155°C and 100rpm. When tested with a biphasic dissolution test, more than 80% of itraconazole was released in the organic phase after 8h. Moreover, this formulation showed the desired thermoformability value. From these results, the design space around the optimum was determined. It corresponds to the limits within which the process would give the optimized product. It was observed that a temperature between 155 and 170°C allowed a high flexibility on the screw speed, from about 75 to 130rpm.


Subject(s)
Itraconazole/chemistry , Calorimetry, Differential Scanning/methods , Chemistry, Pharmaceutical/methods , Drug Carriers/chemistry , Drug Compounding/methods , Drug Stability , Excipients/chemistry , Hot Temperature , Lactose/analogs & derivatives , Lactose/chemistry , Methylcellulose/analogs & derivatives , Methylcellulose/chemistry , Polyethylene Glycols/chemistry , Polymers/chemistry , Polyvinyls/chemistry , Povidone/chemistry , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...